FDA Approved 4 views

Gonadorelin

Synthetic GnRH for gonadotropin stimulation and fertility

Overview

Gonadorelin is a synthetic decapeptide identical in structure to endogenous gonadotropin-releasing hormone (GnRH/LHRH) produced by the hypothalamus. It stimulates the anterior pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), the gonadotropins that control reproductive function. FDA-approved applications include diagnostic testing of pituitary gonadotroph function and treatment of hypogonadotropic hypogonadism when administered in pulsatile fashion. Unlike long-acting GnRH agonists that cause receptor downregulation and suppression, pulsatile gonadorelin maintains physiological gonadotropin secretion patterns. Research supports its use in fertility induction for both men and women with hypothalamic amenorrhea or hypogonadotropic conditions. The peptide is also used in veterinary medicine to induce ovulation. Gonadorelin has a very short half-life requiring frequent administration or specialized pulsatile pump delivery for therapeutic use. In research and clinical settings, it may help restore endogenous testosterone production by stimulating the hypothalamic-pituitary-gonadal axis naturally.

Last reviewed: 2026-08-18

Identity & Aliases

Also known as

GnRHLHRHGonadotropin-releasing hormoneGonadorelin hydrochlorideGonadorelin acetateFactrelLutrepulse

Status: FDA approved

CAS33515-09-2

PubChem638793

Full composition (formula, molecular weight, sequence) in Quick Facts →

Research Areas

Hypogonadotropic hypogonadismFertility / ovulation inductionPituitary function testingDelayed pubertyAssisted reproduction

Available Evidence

Human

Gonadorelin is FDA approved for diagnostic testing of hypothalamic-pituitary-gonadal function and, given by pulsatile pump, for induction of ovulation/menstruation in primary hypothalamic amenorrhea and treatment of hypogonadotropic hypogonadism. It is standard clinical practice, supported by decades of use, though the branded pulsatile delivery products have been discontinued in the US.

Animal

GnRH decapeptide physiology and pulsatile-release requirements are established from extensive animal models of the reproductive axis.

In Vitro

Gonadorelin acts at pituitary gonadotroph GnRH receptors to stimulate LH and FSH release; receptor downregulation with continuous exposure is well documented in cell and receptor studies.

Uncertain

Claims that gonadorelin injections 'restart' natural testosterone production in healthy men on TRT are not supported by robust clinical trials; the peptide's extremely short half-life limits any practical pulsatile dosing outside approved pump systems.

Key Studies & Findings

1 studies

Clinical1989

Gonadorelin (as Factrel/Lutrepulse) is FDA approved for evaluating pituitary gonadotroph function and for pulsatile treatment of primary hypothalamic amenorrhea / hypogonadotropic hypogonadism, establishing its efficacy and safety in these indications.

FDA-approved indications (drug labeling)

Benefits & Effects

6 documented

Fertility support

anecdotal

View Source

Testosterone stimulation

anecdotal

View Source

LH/FSH release

anecdotal

View Source

Reproductive health

anecdotal

View Source

Hypogonadism treatment

anecdotal

View Source

FDA approved

anecdotal

View Source

Side Effects & Safety

7 reported

Mild side effect

MildCommon Reversible

Onset: Hours

Management: Analgesics

View Source

Mild side effect

MildCommon Reversible

Onset: Immediate

Management: Reassurance; self-limiting

View Source

Severe side effect

SevereRare (more with repeat dosing) Reversible

Onset: Minutes

Management: Discontinue; epinephrine

Dose-dependent

View Source

Headache

MildUncommon

View Source

Injection site reactions

MildUncommon

View Source

Nausea

MildUncommon

View Source

Rare allergic reactions

SevereRare

View Source

Limitations & Open Questions

Although FDA approved, the pulsatile delivery system (Lutrepulse) is no longer marketed in the US, so contemporary use relies on compounding or off-label injections with no clinical evidence for testosterone restoration in normal men. Continuous (non-pulsatile) administration paradoxically suppresses gonadotropins.

Pharmacology

Gonadorelin is a synthetic decapeptide identical to endogenous GnRH. Its half-life is very short (minutes), which is why therapeutic pulsatile regimens require frequent dosing or a pump (historically ~5 mcg SC every 90 minutes via Lutrepulse). It acts on pituitary GnRH receptors to release LH and FSH; continuous exposure causes receptor desensitization and suppression.

Reported Research Dosing

Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.

100mcg 2-3x weekly

Route: SC/IV

Half-life: 2-10 minutes

Frequently Asked Questions

What is gonadorelin FDA approved for?

Diagnostic testing of hypothalamic-pituitary-gonadal function and, when delivered pulsatile, treatment of primary hypothalamic amenorrhea and hypogonadotropic hypogonadism.

Why is gonadorelin given pulsatile?

Its half-life is minutes long, and physiological LH/FSH release depends on pulsatile GnRH stimulation; continuous exposure downregulates pituitary receptors and suppresses gonadotropins.

Can gonadorelin restore testosterone in healthy men?

There is no robust clinical trial evidence supporting gonadorelin injections for restoring testosterone in healthy men; its approved uses are diagnostic testing and pulsatile therapy for specific hypogonadal/amenorrhea conditions.